Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 5/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | PRF1 | P14222 | 9/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431366 | 1.00 | UGCG (0.39) | UGCGMKNK1PRF1PIK3CAMTOR | |
| SCHEMBL2627990 | 0.87 | DDB1 (0.44) | UGCGPRF1PARP1DDB1CRBN | |
| SCHEMBL28587410 | 0.84 | GRM5 (0.52) | PRF1GRM5DDB1CRBN | |
| SCHEMBL29956413 | 0.80 | LMNA (0.42) | PRF1PARP1GRM5 | |
| SCHEMBL15850611 | 0.80 | ENPP2 (0.32) | — | |
| SCHEMBL29955396 | 0.80 | PRF1 (0.40) | PRF1GRM5 | |
| SCHEMBL29951312 | 0.80 | KCNH2 (0.42) | PRF1GRM5 | |
| SCHEMBL29951586 | 0.80 | PRF1 (0.42) | PRF1 | |
| SCHEMBL2559421 | 0.78 | PRF1 (0.43) | PRF1PARP1 | |
| SCHEMBL2501696 | 0.78 | PRF1 (0.44) | PRF1PARP1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| EP-3917911-A1 | 15-PGDH INHIBITORS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160151-A1 | 15-PGDH INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160151-A1 | 15-PGDH INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-08-06 | — | — | WO | disclosed |
| EP-3154979-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY. | PFIZER LTD (GB) | 2018-03-07 | — | — | EP | disclosed |
| US-9802945-B2 | Imidazopyridazine derivatives as modulators of the GABAA receptor activity | PFIZER LIMITED (GB) | 2017-10-31 | — | — | US | disclosed |
| US-20170197965-A1 | Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity | PFIZER LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| EP-3154979-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY. | Pfizer Limited (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-8193239-B2 | Substituted 1-cyanoethylheterocyclylcarboxamide compounds | ASTRAZENECA AB (SE) | 2012-06-05 | — | — | US | disclosed |
| US-20120094957-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC. | 2012-04-19 | — | — | US | disclosed |
| US-20120094957-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC. | 2012-04-19 | — | — | US | disclosed |
| EP-2427445-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | AstraZeneca AB (SE) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128324-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128324-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| WO-2010118155-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR2 | UGCG 1852/4885MKNK1 4563/4885PRF1 3283/4885 |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | UGCG 177/4885MKNK1 2508/4885PRF1 2748/4885 |
| US-20120094957-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, FFAR3 | UGCG 405/4885MKNK1 4579/4885PRF1 2080/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | UGCG 3121/4885MKNK1 565/4885PRF1 4717/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | UGCG 177/4885MKNK1 2508/4885PRF1 2748/4885 |
| US-20170197965-A1 | Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity | GABRA5, GABRA3, GABRA2 | UGCG 4807/4885MKNK1 3969/4885PRF1 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.